Tectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Inc TECX.OQ reported a quarterly adjusted loss of $1.18 per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.07. The mean expectation of eight analysts for the quarter was for a loss of $1.35 per share. Wall Street expected results to range from $-1.47 to $-1.25 per share.
Reported revenue was zero; analysts expected zero.
Tectonic Therapeutic Inc's reported EPS for the quarter was a loss of $1.18.
The company reported a quarterly loss of $22.29 million.
Tectonic Therapeutic Inc shares had fallen by 14.0% this quarter and gained 41.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Tectonic Therapeutic Inc is $80.00, about 63.1% above its last closing price of $29.56
This summary was machine generated from LSEG data August 6 at 08:57 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -1.35 | -1.18 | Beat |
Mar. 31 2026 | -1.18 | -1.34 | Missed |
Dec. 31 2025 | -1.10 | -1.03 | Beat |
Sep. 30 2025 | -1.05 | -1.02 | Beat |
Recent news on Tectonic Therapeutic
See all newsTectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Q2 net loss widens on higher costs
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
Tectonic Therapeutic Q1 net loss widens on higher R&D costs